Neoplasia — MCQs
On this page
Which of the following statements regarding carcinoid tumors is not true?
A 56-year-old woman presents with vaginal bleeding for 1 week. Her last menstrual period was 10 years ago. Physical examination reveals a palpable lower abdominal mass. Endometrial biopsy shows endometrial carcinoma, and an abdominal CT scan shows a 6-cm mass in the left ovary. A total abdominal hysterectomy is performed. Microscopically, the ovarian mass is identified as a granulosa-theca cell tumor producing estrogen. Which of the following best describes the relationship between the endometrial carcinoma and the estrogen-producing ovarian tumor?
Both breasts are affected in which type of breast carcinoma?
Which of the following is not a paraneoplastic syndrome of Renal cell carcinoma?
Which gene is associated with superficial papillary urothelial neoplasm?
Deletion of the short arm of chromosome 11 is seen in which of the following conditions?
What type of tumour may occur in the residual breast or overlying skin following wide local excision and radiotherapy for mammary carcinoma?
Which of the following tumors shows increased serum elevation of placental alkaline phosphatase and positive immunohistochemical staining for placental alkaline phosphatase?
The translocation most commonly seen in follicular lymphoma is?
CAR-T cells are used in the treatment of which of the following cancers?
Neoplasia Indian Medical PG Practice Questions and MCQs
Question 511: Which of the following statements regarding carcinoid tumors is not true?
- A. Carcinoid tumors exhibit 4 distinctive histological forms. (Correct Answer)
- B. Extensive involvement of the small intestine is associated with a higher chance of lung involvement.
- C. The 5-year survival rate for carcinoid tumors is greater than 60%.
- D. Eighty percent of appendiceal carcinoids are incidentally detected during surgery for other indications.
Explanation: **Explanation:** **1. Why Option A is the correct answer (False statement):** Carcinoid tumors (Well-differentiated Neuroendocrine Tumors) do not exhibit 4 distinctive histological forms. Instead, they typically show a **monomorphic** appearance [1]. Histologically, they are characterized by islands, nests, or trabeculae of small, uniform cells with "salt and pepper" chromatin and eosinophilic granular cytoplasm [4]. While their growth patterns can vary (insular, trabecular, glandular), they are not classified into four distinct histological types. **2. Analysis of Incorrect Options (True statements):** * **Option B:** Carcinoid syndrome occurs only when tumor products (like serotonin) bypass hepatic metabolism. Extensive small intestinal involvement with **liver metastasis** allows these substances to enter systemic circulation, leading to right-sided heart lesions and potentially reaching the lungs [4]. * **Option C:** Carcinoid tumors are generally slow-growing [2]. The overall 5-year survival rate is high, often exceeding **90%** for localized disease and remaining above **60%** even with regional spread. * **Option D:** The **appendix** is one of the most common sites for carcinoids [3]. Most are small (<2 cm), asymptomatic, and found incidentally during appendectomies or other abdominal surgeries [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Site:** Historically the appendix; however, recent data suggests the **small intestine** (specifically the ileum) and **rectum** are increasingly common [2]. * **Carcinoid Syndrome:** Characterized by flushing, diarrhea, and wheezing. It occurs in <10% of patients, usually only after **liver metastasis** [4]. * **Diagnosis:** 24-hour urinary **5-HIAA** (metabolite of serotonin) is the gold standard for screening. * **Marker:** **Chromogranin A** is a sensitive serum marker for monitoring. * **Heart Involvement:** Primarily affects the **right side** (Tricuspid insufficiency/Pulmonary stenosis) because pulmonary monoamine oxidase degrades serotonin before it reaches the left heart. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, p. 727. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 780-781. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Alimentary System Disease, pp. 375-376. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 781-782.
Question 512: A 56-year-old woman presents with vaginal bleeding for 1 week. Her last menstrual period was 10 years ago. Physical examination reveals a palpable lower abdominal mass. Endometrial biopsy shows endometrial carcinoma, and an abdominal CT scan shows a 6-cm mass in the left ovary. A total abdominal hysterectomy is performed. Microscopically, the ovarian mass is identified as a granulosa-theca cell tumor producing estrogen. Which of the following best describes the relationship between the endometrial carcinoma and the estrogen-producing ovarian tumor?
- A. Genetic susceptibility to tumorigenesis
- B. Mutational inactivation of a tumor suppressor gene
- C. Paraneoplastic syndrome
- D. Promotion of carcinogenesis by estrogen (Correct Answer)
Explanation: ### Explanation **1. Why Option D is Correct:** The core concept here is the role of **hormones as promoters of carcinogenesis**. Estrogen is a potent mitogen for endometrial tissue. In this postmenopausal patient, the granulosa-theca cell tumor (a sex cord-stromal tumor) acts as a source of **unopposed estrogen**. Estrogen does not act as a direct mutagen; instead, it stimulates the proliferation of endometrial cells [1]. This increased mitotic activity (hyperplasia) increases the statistical likelihood of spontaneous mutations occurring during DNA replication. Over time, this leads to the progression from simple hyperplasia to atypical hyperplasia [2], and finally to **Type I Endometrial Adenocarcinoma**. In this context, estrogen is a "promoter" rather than an "initiator." **2. Why Other Options are Incorrect:** * **Option A & B:** While genetic mutations (like *PTEN* or *MSI*) and tumor suppressor inactivation are involved in the development of endometrial cancer, they do not describe the *relationship* between the two specific tumors mentioned. The ovarian tumor is the *cause* of the hormonal environment, not a result of a shared genetic syndrome (like Lynch Syndrome, which typically involves the colon) [1]. * **Option C:** A paraneoplastic syndrome refers to systemic symptoms (like hypercalcemia or Lambert-Eaton) caused by a tumor but not related to direct tumor spread or the physiological function of the tissue of origin. Since granulosa cells physiologically produce estrogen, its overproduction is a functional manifestation of the tumor, not a paraneoplastic phenomenon. **3. Clinical Pearls for NEET-PG:** * **Granulosa Cell Tumor:** Characterized by **Call-Exner bodies** (small follicles filled with eosinophilic material) and "coffee-bean" nuclei. It is the most common estrogen-producing ovarian tumor. * **Tumor Marker:** **Inhibin** is the specific marker used for monitoring granulosa cell tumors. * **Association:** Always suspect an estrogen-secreting ovarian mass in a postmenopausal woman presenting with endometrial hyperplasia or carcinoma. * **Type I vs. Type II Endometrial Cancer:** Type I is estrogen-dependent (favorable prognosis), while Type II (Serous) is estrogen-independent and associated with *p53* mutations (poor prognosis) [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1017-1018. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Female Genital Tract Disease, pp. 473-475.
Question 513: Both breasts are affected in which type of breast carcinoma?
- A. Inflammatory
- B. Infiltrating
- C. Ductal
- D. Lobular (Correct Answer)
Explanation: ### Explanation **Correct Option: D. Lobular Carcinoma** Invasive Lobular Carcinoma (ILC) is uniquely characterized by its high incidence of **multicentricity** (multiple foci within the same breast) and **bilaterality** (involvement of both breasts). [1] * **The Underlying Concept:** The hallmark of ILC is the loss of **E-cadherin** expression (due to mutations in the *CDH1* gene). E-cadherin is a cell-adhesion molecule; its absence leads to the characteristic "single-file" (Indian file) pattern of cell infiltration. [1] This lack of cohesion explains why the tumor often presents as a diffuse, ill-defined thickening rather than a discrete mass and why it frequently involves both breasts (bilaterality is seen in approximately 10–15% of cases). **Why Incorrect Options are Wrong:** * **A. Inflammatory Carcinoma:** This is a clinical diagnosis characterized by "peau d'orange" appearance due to dermal lymphatic invasion. While aggressive, it typically presents unilaterally. * **B & C. Infiltrating/Ductal Carcinoma:** Invasive Carcinoma of No Special Type (formerly Infiltrating Ductal Carcinoma) is the most common type of breast cancer. Unlike lobular carcinoma, it usually presents as a discrete, unilateral mass and has a much lower rate of synchronicity or bilaterality. [1] **High-Yield Pearls for NEET-PG:** 1. **Genetic Marker:** Loss of **E-cadherin** is the most important diagnostic feature of Lobular Carcinoma (both In-situ and Invasive). 2. **Morphology:** Look for "Indian file" arrangement and "targetoid" patterns around ducts. [1] 3. **Metastatic Pattern:** Unlike ductal carcinoma, ILC has a unique tendency to metastasize to the **peritoneum, retroperitoneum, leptomeninges, and ovaries.** 4. **Imaging:** ILC is notorious for being "mammographically silent" because it does not always form a dense, calcified mass. [1] **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 454-455.
Question 514: Which of the following is not a paraneoplastic syndrome of Renal cell carcinoma?
- A. Erythrocytosis
- B. Amyloidosis
- C. Cushing's syndrome (Correct Answer)
- D. Hypertension
Explanation: **Explanation:** Renal Cell Carcinoma (RCC) is famously known as the **"Internist’s Tumor"** because of its propensity to present with a wide array of paraneoplastic syndromes (PNS) [1]. **Why Cushing’s Syndrome is the Correct Answer:** Cushing’s syndrome is caused by the ectopic production of **ACTH**. While it is a classic PNS for **Small Cell Carcinoma of the Lung** and Medullary Thyroid Carcinoma, it is **not** typically associated with RCC [1]. RCC is more commonly associated with ectopic production of PTHrP (Hypercalcemia), Erythropoietin, and Renin. **Analysis of Incorrect Options:** * **Erythrocytosis:** Occurs in ~5-10% of RCC patients due to the ectopic secretion of **Erythropoietin (EPO)** by the tumor cells [2]. * **Amyloidosis:** Chronic inflammation and tumor-related proteins in RCC can lead to **Secondary (AA) Amyloidosis**. This is a recognized systemic complication of the disease. * **Hypertension:** This is a common PNS in RCC, occurring due to the secretion of **Renin** by the tumor or due to compression of the renal artery (Goldblatt kidney mechanism). **High-Yield Clinical Pearls for NEET-PG:** * **Stauffer Syndrome:** A unique PNS of RCC characterized by reversible hepatic dysfunction (elevated LFTs) in the absence of liver metastases. * **Most Common PNS in RCC:** Hypercalcemia (due to PTHrP) [1]. * **Classic Triad:** Hematuria, flank pain, and palpable mass (seen in only 10% of cases; usually signifies advanced disease). * **Genetic Association:** Deletion of the **VHL gene** on Chromosome 3p is the most common genetic defect in sporadic and familial clear cell RCC. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 338-339. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 492-493.
Question 515: Which gene is associated with superficial papillary urothelial neoplasm?
- A. p53
- B. p16 (Correct Answer)
- C. p7
- D. KRAS
Explanation: **Explanation:** The molecular pathogenesis of bladder cancer follows two distinct pathways. The **superficial (papillary) pathway** typically involves low-grade tumors that frequently recur but rarely progress to invasive disease [4]. The **p16 gene** (encoded by *CDKN2A* on chromosome 9p21) is the most common genetic alteration in these superficial papillary urothelial neoplasms [1]. Loss of p16 leads to uncontrolled cell cycle progression through the G1-S checkpoint [1]. **Analysis of Options:** * **p16 (Option B):** Correct. Deletions or mutations of the *CDKN2A* locus (p16/INK4a) are hallmark early events in the development of non-invasive, low-grade papillary urothelial carcinomas [1]. * **p53 (Option A):** Incorrect. Mutations in *TP53* are characteristic of the **invasive (flat) pathway**. They are associated with high-grade Carcinoma in Situ (CIS) and muscle-invasive bladder cancer, indicating a poorer prognosis. * **p7 (Option C):** Incorrect. There is no significant association between a "p7" gene and urothelial neoplasia in standard pathology. * **KRAS (Option D):** Incorrect. While *RAS* mutations occur in various cancers (like colon or lung), they are not the primary drivers for superficial papillary bladder tumors [2]. **NEET-PG High-Yield Pearls:** * **Two-Pathway Model:** 1. **Papillary Pathway:** *FGFR3* mutations and *p16 (9p21)* deletions (Low grade/Superficial). 2. **Flat/Invasive Pathway:** *TP53* and *RB* mutations (High grade/Invasive). * **Schistosoma haematobium:** Associated with **Squamous Cell Carcinoma** of the bladder, not urothelial carcinoma [3]. * **Field Cancerization:** The entire urothelium is at risk due to exposure to carcinogens (e.g., smoking, aniline dyes), leading to multifocal tumors [4]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 305-306. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 897-898. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 968-970. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 495-496.
Question 516: Deletion of the short arm of chromosome 11 is seen in which of the following conditions?
- A. Osteosarcoma
- B. Meningioma
- C. Wilms tumor (Correct Answer)
- D. Colon carcinoma
Explanation: ### Explanation **Correct Option: C. Wilms tumor** Wilms tumor (Nephroblastoma) is the most common primary renal tumor of childhood. The pathogenesis is closely linked to the **WT1 gene**, located on the **short arm of chromosome 11 (11p13)** [1]. Deletions or mutations in this region lead to the loss of this tumor suppressor gene, which is essential for normal renal and gonadal development. This deletion is classically associated with **WAGR syndrome** (Wilms tumor, Aniridia, Genitourinary anomalies, and intellectual disability/Range of developmental delays) [1]. **Analysis of Incorrect Options:** * **A. Osteosarcoma:** Most commonly associated with mutations in the **RB1 gene (13q14)** and **TP53 gene (17p13)**. While 11p abnormalities are not characteristic, hereditary retinoblastoma patients have a significantly high risk for osteosarcoma. * **B. Meningioma:** Characterized by the deletion or mutation of the **NF2 gene** located on the **long arm of chromosome 22 (22q12)**. * **D. Colon carcinoma:** Primarily associated with the **APC gene (5q21)** in familial adenomatous poplyposis (FAP) and the **DCC gene (18q21)** in the adenoma-carcinoma sequence. **High-Yield Clinical Pearls for NEET-PG:** * **WT1 (11p13):** Associated with WAGR syndrome and Denys-Drash syndrome [1]. * **WT2 (11p15.5):** Associated with **Beckwith-Wiedemann Syndrome** (macroglossia, hemihypertrophy, and organomegaly). * **Histology Triad:** Wilms tumor typically shows a triphasic pattern consisting of **blastemal, stromal, and epithelial** cells. * **Prognostic Marker:** The presence of **anaplasia** (TP53 mutation) is the most important adverse prognostic factor in Wilms tumor. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 487-488.
Question 517: What type of tumour may occur in the residual breast or overlying skin following wide local excision and radiotherapy for mammary carcinoma?
- A. Leiomyosarcoma
- B. Squamous cell carcinoma
- C. Basal cell carcinoma
- D. Angiosarcoma (Correct Answer)
Explanation: **Explanation:** The development of a malignant vascular tumor in the breast or overlying skin following breast-conserving surgery (wide local excision) and radiotherapy is a classic presentation of **Radiation-Induced Angiosarcoma (RIAS)**. **Why Angiosarcoma is correct:** Angiosarcoma is a rare but well-recognized complication of radiotherapy. It typically occurs after a latent period of **5 to 10 years** post-irradiation. It can also occur in the setting of chronic lymphedema following axillary lymph node dissection, a phenomenon known as **Stewart-Treves Syndrome**. Clinically, it presents as painless, bruise-like purple skin nodules or plaques that rapidly enlarge [1]. Histologically, it shows malignant endothelial cells forming irregular vascular channels [1]. **Why other options are incorrect:** * **Leiomyosarcoma:** This is a malignant tumor of smooth muscle origin. While sarcomas can be radiation-induced, leiomyosarcoma is extremely rare in the breast and not specifically associated with post-radiotherapy breast changes. * **Squamous cell carcinoma (SCC) & Basal cell carcinoma (BCC):** These are common skin cancers usually associated with UV radiation. While chronic radiation dermatitis can predispose to SCC, Angiosarcoma is the specific, high-yield association for post-mastectomy/post-radiotherapy breast pathology in medical exams. **High-Yield Clinical Pearls for NEET-PG:** * **Latent Period:** Usually 5–10 years for radiation-induced angiosarcoma. * **Stewart-Treves Syndrome:** Angiosarcoma arising in a limb with chronic lymphedema (classically post-radical mastectomy). * **Marker:** **CD31** (most specific) and **CD34** are positive immunohistochemical markers for Angiosarcoma [1]. * **Genetic Association:** Amplification of the **MYC gene** on chromosome 8 is frequently seen in radiation-induced angiosarcomas but not in primary ones. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 527-528.
Question 518: Which of the following tumors shows increased serum elevation of placental alkaline phosphatase and positive immunohistochemical staining for placental alkaline phosphatase?
- A. Seminoma (Correct Answer)
- B. Hepatoblastoma
- C. Hepatocellular carcinoma
- D. Peripheral neuroectodermal tumor
Explanation: **Explanation:** **Seminoma** is the most common germ cell tumor of the testis. It characteristically expresses **Placental Alkaline Phosphatase (PLAP)**, which serves as both a serum marker and a highly sensitive immunohistochemical (IHC) marker [1]. PLAP is an enzyme normally produced by the placenta; its elevation in a male patient is highly suggestive of a germ cell origin, specifically seminoma or dysgerminoma (its female counterpart). **Analysis of Options:** * **A. Seminoma (Correct):** Shows diffuse membranous positivity for PLAP, c-KIT (CD117), and OCT3/4 [1]. Serum PLAP levels are elevated in approximately 40-50% of cases. * **B. Hepatoblastoma:** This is a childhood liver tumor. Its primary markers are **Alpha-fetoprotein (AFP)** and Beta-catenin (nuclear staining). * **C. Hepatocellular Carcinoma (HCC):** The classic serum marker is **AFP**. IHC markers include HepPar-1, Glypican-3, and Arginase-1. * **D. Peripheral Neuroectodermal Tumor (PNET/Ewing Sarcoma):** These belong to the small round blue cell tumor family. The characteristic IHC marker is **CD99 (MIC2)**, and they are associated with the t(11;22) translocation. **NEET-PG High-Yield Pearls:** 1. **Seminoma vs. Non-Seminoma:** Seminomas *never* produce AFP. If AFP is elevated, it indicates a non-seminomatous component (like Yolk Sac Tumor). 2. **HCG in Seminoma:** About 10-15% of seminomas contain syncytiotrophoblastic giant cells which can cause a mild elevation in serum **beta-HCG** [1]. 3. **Classic IHC Triad for Seminoma:** PLAP (+), CD117 (+), and OCT3/4 (+). Note that CD30 is typically negative (positive in Embryonal Carcinoma) [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 980-982.
Question 519: The translocation most commonly seen in follicular lymphoma is?
- A. t(11;14)
- B. t(14;18) (Correct Answer)
- C. t(9;22)
- D. t(8;14)
Explanation: **Explanation:** **Follicular Lymphoma (FL)** is a B-cell neoplasm characterized by the translocation **t(14;18)(q32;q21)** [1],[3]. * **Mechanism:** This translocation involves the fusion of the **BCL-2 gene** (on chromosome 18) with the **Immunoglobulin Heavy chain (IgH) locus** (on chromosome 14) [1]. * **Pathophysiology:** The IgH promoter is constitutively active in B-cells, leading to the massive overexpression of the BCL-2 protein [2]. BCL-2 is an **anti-apoptotic** protein that stabilizes the mitochondrial membrane [3]. Its overexpression prevents programmed cell death (apoptosis) of B-cells, leading to their accumulation in the germinal centers of lymph nodes [1]. **Analysis of Incorrect Options:** * **t(11;14):** Characteristic of **Mantle Cell Lymphoma**. It involves the *Cyclin D1* gene (PRAD1), leading to cell cycle progression. * **t(9;22):** Known as the **Philadelphia Chromosome**, characteristic of **Chronic Myeloid Leukemia (CML)** and some cases of ALL. It creates the *BCR-ABL1* fusion protein with tyrosine kinase activity. * **t(8;14):** Characteristic of **Burkitt Lymphoma**. It involves the *c-MYC* proto-oncogene [2], leading to rapid cellular proliferation (Starry-sky appearance). **High-Yield Clinical Pearls for NEET-PG:** * **Morphology:** FL shows a nodular/follicular growth pattern [3]. Centrocytes (cleaved cells) and centroblasts are seen. * **Immunophenotype:** Positive for CD19, CD20, CD10, and BCL-2 (Normal germinal centers are BCL-2 negative) [1]. * **Transformation:** FL can transform into a more aggressive **Diffuse Large B-Cell Lymphoma (DLBCL)** (Richter’s transformation) [4]. * **Clinical:** Typically presents as painless, generalized lymphadenopathy in older adults with an indolent (waxing and waning) course. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 602-604. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 310-311. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 561-562. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 563-564.
Question 520: CAR-T cells are used in the treatment of which of the following cancers?
- A. Acute lymphoblastic leukemia (Correct Answer)
- B. Soft tissue sarcoma
- C. Medulloblastoma
- D. Small cell lung carcinoma
Explanation: **Explanation:** **Chimeric Antigen Receptor (CAR) T-cell therapy** is a revolutionary form of adoptive immunotherapy where a patient’s T-cells are genetically engineered to express a synthetic receptor that recognizes specific tumor antigens without the need for MHC presentation. **Why Option A is Correct:** The most successful application of CAR-T therapy to date is in B-cell malignancies. The engineered T-cells typically target **CD19**, a surface marker found on almost all B-cells. **Acute Lymphoblastic Leukemia (ALL)**, specifically B-ALL, shows high expression of CD19, making it highly susceptible to this therapy. It is currently FDA-approved for relapsed or refractory B-cell ALL in children and young adults [1]. **Why Other Options are Incorrect:** * **Options B, C, and D (Soft tissue sarcoma, Medulloblastoma, Small cell lung carcinoma):** These are all **solid tumors**. CAR-T therapy faces significant challenges in solid tumors due to the lack of unique tumor-specific antigens, poor penetration into the dense tumor microenvironment, and local immunosuppressive factors. While research is ongoing, they are not currently standard indications for CAR-T therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Target Antigen:** Most common target is **CD19** (used in Tisagenlecleucel and Axicabtagene ciloleucel). * **Major Side Effect:** **Cytokine Release Syndrome (CRS)**, characterized by high fever and hypotension due to massive release of IL-6. * **Management of CRS:** The IL-6 receptor antagonist **Tocilizumab** is the drug of choice. * **Neurotoxicity:** Also known as ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome), it is the second most common serious side effect. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 635-636.
Practice by Chapter
Nomenclature and Classification of Tumors
Practice Questions
Characteristics of Benign and Malignant Neoplasms
Practice Questions
Molecular Basis of Cancer
Practice Questions
Carcinogenesis and Carcinogens
Practice Questions
Tumor Progression and Metastasis
Practice Questions
Tumor Markers
Practice Questions
Paraneoplastic Syndromes
Practice Questions
Genetic Basis of Cancer
Practice Questions
Tumor Immunity
Practice Questions
Cancer Epidemiology and Prevention
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free